Head-to-head · WeighScore
Oak vs Sesame Care
By GLP-1 ScorecardUpdated
Score comparison
Sesame Care has the higher recorded score — 87.8/100 to 63.2/100.
Sesame Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Choose a provider for Wegovy, Zepbound and oral GLP-1 options through Sesame; care and medication are billed separately, and the annual care headline needs comparison with the shorter plan.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Oak | Sesame Care |
|---|---|---|
| WeighScore | 63.2/100 | 87.8/100 |
| Grade | C | B+ |
| Site position | #221 | #2 |
| Semaglutide | From $119/mo on a 12-month plan; quarterly or upfront billing depends on selected plan; actual dose, supply and charge unverified | Brand Wegovy pill from $149/mo at 1.5/4 mg; $299 at 9/25 mg, plus required care: from $59/mo on annual subscription or $99 every 28 days (confirm billing) |
| Tirzepatide | From $185/mo on a 12-month plan; quarterly or upfront billing depends on selected plan; actual dose, supply and charge unverified | Brand Zepbound vials from $299/mo at 2.5 mg; higher doses cost more and KwikPen pages conflict, plus required care (confirm selected product and billing) |
| Coverage | Confirm selected treatment and state: homepage promotes a 50-state provider network, while terms say 45 states or certain states | U.S. marketplace; provider and treatment availability varies; confirm your state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Site position #221 · C
Strengths
- Current semaglutide and tirzepatide product pages explicitly identify the twelve-month term behind advertised starting rates
- Monthly and three-month plans have no cancellation fee before the next charge under the current refund section
- The policy specifies a medical-stop exception, prepaid future-month refund calculation and a limit on quarterly-plan discount repayment
- Branded pens and Oral Wegovy tablets are now advertised alongside compounded injections; availability and exact prices require confirmation
What to consider
- The $119/$185 rates do not establish a monthly debit, dose-independent price or usable shipment supply
- Leaving a six- or twelve-month quarterly plan early can repay discounts on months received, capped at one quarterly payment
- Orders already sent to the pharmacy are final; stopping the account does not refund them
- The same terms page retains inconsistent company names, membership-fee language and state-availability statements
- The public material reviewed did not establish the assigned medical practice, individual prescriber or dispensing pharmacy legal name and address
Site position #2 · B+
Strengths
- Provider choice with advertised video visits, follow-ups and continuing messaging
- Branded injection and oral options are described, subject to prescribing, dose, insurance and pharmacy availability
- Quest lab costs are included except in nine named states; alternative lab coverage requires confirmation
- The current semaglutide page explicitly distinguishes branded products from compounded semaglutide, which it says is currently unavailable
What to consider
- The $59 care headline requires an annual subscription and excludes medication; provider-specific care rates may be higher
- Ordinary care is called monthly but also billed every 28 days; longer-term savings arithmetic needs confirmation
- Program refund wording differs from newer terms describing multi-month repricing and a 48-hour renewal notice
- Drug prices depend on dose and promotion; official KwikPen and Foundayo displays contain discrepancies
- The selected clinician, medical practice and dispensing pharmacy were not established by this review
Featured provider
Sesame Care
Sesame Care scores 87.8/100 (B+). Choose a provider for Wegovy, Zepbound and oral GLP-1 options through Sesame; care and medication are billed separately, and the annual care headline needs comparison with the shorter plan.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.